A New Jersey queso fresco manufacturer’s ignored U.S. Food and Drug Administration (FDA) warnings culminated in a federal guilty plea after its products were linked to a multistate listeria outbreak that hospitalized at least 13 people and killed one. The case of Abuelito Cheese Inc. illustrates how regulatory noncompliance, left unaddressed, can escalate from civil enforcement into criminal liability under the Federal Food, Drug, and Cosmetic Act (FDCA).

The Regulatory Red Flags and Outbreak

According to an information announced on May 21, 2026, in January and February 2020, the FDA conducted an inspection of Abuelito Cheese’s manufacturing facility in Paterson, NJ. Investigators swabbed facility surfaces and detected the presence of strains of listeria bacteria. The FDA issued a report to the company containing multiple observations reflecting potential violations of FDA regulations, including the absence of a written food safety plan, the company’s failure to monitor sanitizer solution for strength and effectiveness, and the company’s failure to visually check or record refrigerator temperature.

Abuelito Cheese responded in February 2020 with a description of corrective actions. But the FDA was not satisfied. On June 8, 2020, the agency issued a formal warning letter stating that it continued to have serious concerns regarding the company’s violation of FDA regulations. Critically, the warning letter cautioned that the presence of nonpathogenic listeria strains at the facility indicated that conditions were conducive for pathogenic Listeria monocytogenes — the strain that causes listeriosis — to be present. Abuelito Cheese again responded with a description of corrective actions in late June 2020.

Despite these warnings and representations regarding corrective actions, conditions at the facility apparently did not improve. In or around February 2021, the Centers for Disease Control, public health and regulatory officials in several states, and the FDA began investigating a multistate outbreak of Listeria monocytogenes infections. The investigation linked the outbreak to Abuelito Cheese’s queso fresco products. On February 19, 2021, Abuelito Cheese recalled all queso fresco products after being notified by the FDA of the connection, later expanding its recall to include other products made at the same facility. The outbreak resulted in at least 13 hospitalizations and one death across four states.

The Criminal Case

The U.S. Attorney for the District of New Jersey charged Abuelito Cheese with introducing adulterated food into interstate commerce in violation of 21 U.S.C. §§ 331(a) and 333(a)(1). The government alleged that between January 2020 and February 19, 2021, the company introduced and delivered for introduction into interstate commerce queso fresco cheese that was adulterated because it was prepared, packed, and held under insanitary conditions whereby it may have been rendered injurious to health.

On May 22, 2026, Abuelito Cheese pled guilty before U.S. Magistrate Judge Cari Fais. The company faces a maximum potential penalty of five years of probation and a fine of $500,000, or twice the gross gain or loss from the offense, whichever is greatest. Sentencing is scheduled for October 15, 2026. The government is also seeking forfeiture of all adulterated food that Abuelito Cheese introduced into interstate commerce, the value of which was approximately $658,430.

Why It Matters

  • Regulatory warnings are the starting gun, not the finish line. The FDA’s 2020 inspection findings and warning letter were not merely administrative paperwork — they established a documented record that Abuelito Cheese had actual knowledge of the contamination risk at its facility. When the company continued to produce and distribute products under those same insanitary conditions and an outbreak followed, the government had a clear pathway from regulatory violation to criminal prosecution.
  • The FDCA’s criminal provisions have real teeth. Even for companies that can absorb the penalties of probation and fines, a corporate guilty plea carries significant collateral consequences, including reputational damage, potential debarment from government contracts, and enhanced scrutiny of any future operations. The forfeiture allegation, valued at approximately $658,430, adds a direct financial sting.
  • Food manufacturers ignore FDA communications at their peril. This case is a reminder that the FDA’s escalating enforcement tools — inspectional observations, warning letters, and ultimately referrals to the Department of Justice — form a continuum. Warning letters are not suggestions. A failure to genuinely remediate the identified deficiencies can transform a regulatory matter into a criminal one, particularly when the foreseeable harm materializes.